Background: Lack of wearability options is a top cited barrier to insulin pump therapy. A new tubed insulin pump, Tandem Mobi, has a very small footprint (2 x 1.5 x .5 inches), and optional 5-inch tubing and adhesive sleeve for on-body wear, in addition to traditional wear options. Here we qualitatively assess<u> </u>feedback from early users, specifically to understand new options for wearing the system.
Methods: Adults (18+ years) with type 1 diabetes participated in an early product launch October-December 2023 (n=145), and wore the Tandem Mobi for >6 weeks (prior therapy = 83% Tandem t:slim X2, 12% other pumps, 5% multiple daily injections). Daily surveys were sent for open-ended user experience feedback. A total of 309 verbatim comments on the topic of wearability were received and analyzed.
Results: 102 adults using Tandem Mobi responded to surveys. Fifty-seven participants commented on using the adhesive sleeve with 5-inch tubing for on-body wear (figure). Other wear options mentioned included using pump case attached to clothing, or tucking into a pocket or bra. 15% of respondents mentioned the Tandem Mobi wearability allowed them to “forget they are wearing a pump.”
Conclusions: The Tandem Mobi’s on-body wear combined with the ability to disconnect presents a new paradigm for pump wearability. Users cite the convenience of a patch pump with the utility of a tubed pump, potentially reducing barriers to insulin pump therapy by increasing optionality.
S. Habif: Employee; Tandem Diabetes Care, Inc. M.L. Manning: Employee; Tandem Diabetes Care, Inc. S. Leas: Employee; Tandem Diabetes Care, Inc. L. Morgan: Employee; Tandem Diabetes Care, Inc. Stock/Shareholder; Tandem Diabetes Care, Inc. L.H. Messer: Employee; Tandem Diabetes Care, Inc.
Tandem Diabetes Care
